China Money Network
Login
Join

Chinese Biopharma Firm Adlai Nortye Raises $100M In Series C Round

  • September 1, 2020 — 10:05 CST

This Data Is Locked!

This area is available only to Subscribers.

Adlai Nortye, a Chinese clinical-stage biopharmaceutical company focusing on developing immuno-oncology medicines., has raised nearly US$100 million in a series C round financing, led by... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: